Work

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.504

Authors: Laura Ann Huppert, Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, Amy Jo Chien, Christina Yau, Denise M. Wolf, Donald A. Berry, Laura van 't Veer, Douglas Yee, Angela DeMichele, Laura Esserman

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Yale University, Buck Institute for Research on Aging, Berry Consultants, LLC (United States), University of Minnesota, Masonic Cancer Center, Abramson Cancer Center, University of Pennsylvania

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4281705804

Cites:

Cited by: 14

Related to: 10